Latest news with #Iceland-based
Boston Globe
3 days ago
- Business
- Boston Globe
Play Airlines drops US flights to Iceland, while Arajet announces Boston to Dominican Republic service this fall
Play began service at Logan in spring 2022. Play was formed after WOW, another low-cost, Iceland-based airline, went out of business. The same management team from WOW formed Play. In 2022, Play CEO Birgir Jónsson stated that WOW had failed because the airline had grown too quickly. Play never grew too quickly, but instead was plagued by an oversaturated market. In addition to dropping US routes, the airline is also cutting back flights within Europe. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up While Boston is losing Play, it's gaining the low-cost airline Advertisement Arajet will offer four direct flights per week from Boston to Santo Domingo on Wednesdays, Thursdays, Fridays, and Sundays. Advertisement 'We are catering to the large Latin and Dominican diaspora in the greater Boston area by delivering more affordable, convenient flight options so families can reconnect, and travelers can explore the Dominican Republic and beyond,' Arajet CEO Victor Pacheco said in a statement announcing the service. New routes this spring Since late April, several airlines have introduced new routes out of Logan. These include: Delta Air Lines Boston to Barcelona: 3 weekly flights, started May 22. Boston to Milan: 4 weekly flights, started May 23rd. JetBlue Boston to Madrid, daily, started May 22. Boston to Edinburgh daily, started May 22. Boston to Wilmington, N.C., daily, began April 30. Boston to Norfolk, Va., daily, began April 30. TAP Air Boston to Porto, 4 weekly flights, started May 14. Allegiant Boston to Savannah, 2 weekly flights, started May 22. Boston to Des Moines, 2 weekly flights, started May 23. Christopher Muther can be reached at
Yahoo
12-06-2025
- Business
- Yahoo
This Budget Airline Is Canceling All U.S. Flights—What Travelers Should Know
Discount carrier Play Airlines will suspend all flights to the United States in October. The airline operates flights between the U.S., Iceland, and Europe. Passengers will have the opportunity to get a refund or rebook in different cities. It's the final boarding call for U.S. flights from a popular low-cost Play Airlines recently announced it would stop operations to and from the United States, as well as all of North America, this fall. 'All flights to North America cease as of October 2025,' the airline confirmed in a statement on its website. The airline first launched flights to the U.S. in 2021 and currently operates routes from Baltimore, Boston, and New York to Reykjavik, Iceland. Once in Iceland, travelers had the opportunity to fly to a variety of European destinations including Berlin, Copenhagen, Dublin, London, and Porto. Despite October being the announced date for the end of operations, the airline is no longer selling any tickets for travel from New York to Iceland after Sept. 1, 2025. Tickets on the route for travel on Sept. 1 are currently going for as little as €174 one-way (approximately $201). While the airline operates flights out of New York, it does not use the main airports like LaGuardia Airport (LGA), John F. Kennedy International Airport (JFK), or Newark International Airport (EWR). Instead, it uses New York Stewart International Airport (SWF) in Windsor, New York, which is approximately 77 miles north of New York City. Although that is a significant distance from the city, the airport often provides a discounted option for travelers and a regular shuttle service. A representative for the airline told Travel + Leisure that Play would contact all affected passengers for trip modification or refunds if needed. In addition to the end of the airline's North America flights, Play will also undergo a restructure and switch from its existing Iceland-based Air Operator Certificate, to a Maltese-based certificate. The airline will also remove its stock exchange listing and fly to fewer destinations. It will also lease aircraft to other vendors. The decision of Play Airlines to end U.S. flights comes at a time when other airlines have reduced routes or shut down. For example, Silver Airways, a regional airline that operates flights throughout the Bahamas, the Caribbean Islands, and Florida, recently announced a sudden shut down as well. Read the original article on Travel & Leisure
%3Amax_bytes(150000)%3Astrip_icc()%2FTAL-play-airlines-plane-PLAYSALE1223-cc7c22c387534a85aa09d211c9fe50a7.jpg&w=3840&q=100)
Travel + Leisure
12-06-2025
- Business
- Travel + Leisure
This Budget Airline Is Canceling All U.S. Flights—What Travelers Should Know
It's the final boarding call for U.S. flights from a popular low-cost airline. Iceland-based Play Airlines recently announced it would stop operations to and from the United States, as well as all of North America, this fall. 'All flights to North America cease as of October 2025,' the airline confirmed in a statement on its website. The airline first launched flights to the U.S. in 2021 and currently operates routes from Baltimore, Boston, and New York to Reykjavik, Iceland. Once in Iceland, travelers had the opportunity to fly to a variety of European destinations including Berlin, Copenhagen, Dublin, London, and Porto. Despite October being the announced date for the end of operations, the airline is no longer selling any tickets for travel from New York to Iceland after Sept. 1, 2025. Tickets on the route for travel on Sept. 1 are currently going for as little as €174 one-way (approximately $201). While the airline operates flights out of New York, it does not use the main airports like LaGuardia Airport (LGA), John F. Kennedy International Airport (JFK), or Newark International Airport (EWR). Instead, it uses New York Stewart International Airport (SWF) in Windsor, New York, which is approximately 77 miles north of New York City. Although that is a significant distance from the city, the airport often provides a discounted option for travelers and a regular shuttle service. A representative for the airline told Travel + Leisure that Play would contact all affected passengers for trip modification or refunds if needed. In addition to the end of the airline's North America flights, Play will also undergo a restructure and switch from its existing Iceland-based Air Operator Certificate, to a Maltese-based certificate. The airline will also remove its stock exchange listing and fly to fewer destinations. It will also lease aircraft to other vendors. The decision of Play Airlines to end U.S. flights comes at a time when other airlines have reduced routes or shut down. For example, Silver Airways, a regional airline that operates flights throughout the Bahamas, the Caribbean Islands, and Florida, recently announced a sudden shut down as well.
Time of India
05-06-2025
- Business
- Time of India
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda HYDERABAD: Dr Reddy's Laboratories has entered into a collaboration and license agreement with Iceland-based biotech player Alvotech for the co-development, manufacturing and commercialiation of a biosimilar of Merck Sharp & Dohme's blockbuster drug Keytruda (pembrolizumab). Keytruda, which is used for the treatment of various types of cancer, clocked sales of over US$29.5 billion in 2024. The collaboration will combine Dr Reddy's and Alvotech's capabilities in biosimilars to speed up the development process and extend the global reach of the biosimilar candidate. As per the agreement, the two companies will share the costs and responsibilities for jointly developing and manufacturing the biosimilar candidate and subject to certain exceptions, each company will have the right to commercialise the product globally, Dr Reddy's said on Thursday. 'The agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide,' said Róbert Wessman, chairman & CEO, Alvotech. Dr Reddy's CEO, Erez Israeli, said the pact demonstrates the company's ability to develop and manufacture high-quality and affordable treatment options for patients worldwide. 'Oncology has been a top focus therapy area for us, and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' Israeli added. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
&w=3840&q=100)
Business Standard
05-06-2025
- Business
- Business Standard
Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda
Global biotech major Alvotech and Hyderabad-based Dr Reddy's Laboratories (DRL) have entered into a collaboration to co-develop, manufacture, and commercialise a biosimilar version of Merck's blockbuster cancer drug Keytruda (pembrolizumab), which recorded global sales of $29.5 billion in 2024. Shares of DRL rose 3 per cent on Thursday on the BSE following the announcement. Under the agreement, both parties will jointly manage development and manufacturing responsibilities, while sharing associated costs. Each company will also hold global commercialisation rights, subject to certain exceptions. Keytruda, developed by Merck & Co., is used to treat a wide range of cancers, including lung, melanoma, and head and neck cancers. With patents for Keytruda expected to expire in major markets over the next few years, competition among biosimilar developers is intensifying. The partnership is a strategic boost to Dr Reddy's oncology portfolio—a key therapeutic area for the company—and significantly expands Iceland-based Alvotech's biosimilar pipeline. The tie-up comes amid growing global demand for cost-effective biologic alternatives in cancer care, especially in immuno-oncology, where Keytruda remains a dominant therapy. 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar,' said Erez Israeli, CEO of Dr Reddy's. 'Oncology has been a top focus therapy area for us, and this collaboration further enhances our capabilities.' Alvotech Chairman and CEO Róbert Wessman said the partnership would accelerate development while broadening global access to critical biologics. 'This agreement demonstrates our ability to leverage our R&D and manufacturing platform to pursue growing global markets,' he said. Alvotech, listed on Nasdaq, is focused solely on biosimilars and already has approvals for adalimumab and ustekinumab biosimilars. Its pipeline includes candidates for autoimmune, respiratory, and oncologic indications. Dr Reddy's, which has commercialised six biosimilars in India and over 30 countries, has been scaling up global biologics operations. It launched its first biosimilar in the UK—Versavo (bevacizumab)—in 2024, and pegfilgrastim in the US and Europe through partners. With this collaboration, both companies aim to play a larger role in shaping the next phase of affordable cancer care globally.
